… -2 infection diagnosis, dead on or before the SARS-CoV-2 infection diagnosis, or residents
in residential care homes for the elderly. We excluded patients with drug contraindications to …

… NMV-r has multiple and significant drug-drug interactions (DDIs), since included ritonavir is
… (nirmatrelvir/ritonavir)” was issued by the Japanese Society of Pharmaceutical Health Care …

… Further studies are needed to examine the real-world safety and effectiveness of oral antivirals
in specific healthcare settings, for instance, nursing homes and residential care facilities. …

… Nirmatrelvir/ritonavir (Paxlovid, Pfizer) is a combination protease inhibitor that prevents
viral … This analysis summarises what is currently known about nirmatrelvir/ritonavir and the …

… Additionally, procedures in place in some skilled nursing facilities or elder home care programs
encourage admission in context of COVID-19 pre-emptively or for infection control. While …

… nirmatrelvir/ritonavir were compared with infected ones not receiving nirmatrelvir/ritonavir …
were also excluded, because they are likely to be treated in long-term care facilities and this …

… Last, rollout of nirmatrelvir-ritonavir has occurred during … cases receiving nirmatrelvir-ritonavir
in ambulatory care settings, … the effectiveness of nirmatrelvir-ritonavir in preventing severe …

… the trial cohort to treatment with nirmatrelvir-ritonavir to identify DDIs with … time of
nirmatrelvir-ritonavir exposure, and/or (2) deprescribing at the approximate time of …

… Included patients had a positive SARS-CoV-2 test or nirmatrelvir–ritonavir … a
nirmatrelvir–ritonavir order. We propensity score matched patients treated with nirmatrelvir–ritonavir …

… the safety and efficacy of nirmatrelvir/ritonavir in preventing severe … , and the efficacy of
nirmatrelvir/ritonavir is evaluated in a … the impact of nirmatrelvir/ritonavir and determine strategy …